BMJ talk medicine

Dr Philip Smith, Digital and Education Editor of Gut and Consultant Gastroenterologist at the Royal Liverpool Hospital interviews Professor Patrice Cani, Louvain Drug Research Institute, WELBIO, Metabolism and Nutrition, UCLouvain, Brussels, Belgium and Emilie Moens de Hase a PhD student in the same institution.

This Gut podcast is focused on the paper "Dysosmobacter welbionis is a newly isolated human commensal bacterium preventing diet-induced obesity and metabolic disorders in mice" which is published in paper copy in Gut in March 2022, and is available here: https://gut.bmj.com/content/71/3/534

Please subscribe to the Gut Podcast via all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify, to get the latest podcast every month. If you enjoy our podcast, please consider leaving us a review or a comment on the Gut Podcast iTunes page (https://podcasts.apple.com/gb/podcast/gut-podcast/id330976727).

Duane Peters from the Lupus Foundation of America interviews Professor Iryna Kulyk from Indiana University in the USA and Professor Martin Kriegel from the University of Münster in Germany and Yale University in the USA. They discuss their study, presented at the Lupus 21st Century conference in September 2021, on the influence of the consumption of resistant starch (a type of dietary fiber) on the composition of the gut microbiota of lupus patients.

Access the abstract here: https://lupus.bmj.com/content/8/Suppl_2/A63.2.abstract

In this episode of the Heart podcast, Digital Media Editor, Dr James Rudd, is joined by Dr Meghan Reading Turchioe from Weill Cornell Medicine in New York. They discuss a systematic review of the use of natural language processing in cardiology, and how it might improve patient care. If you enjoy the show, please leave us a review at https://itunes.apple.com/gb/podcast/heart-podcast/id445358212?mt=2 or wherever you get your podcasts.

Link to published paper: https://heart.bmj.com/content/early/2021/10/27/heartjnl-2021-319769

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Robert Coleman to discuss TV in Advanced or Recurrent Cervical Cancer.

HIGHLIGHTS:

Drug development in cervix cancer has undergone a renaissance in recent years with the identification of novel antibody drug conjugates (ADC) and immunotherapy measurably impacting patient survivorship.

Tisotumab vedotin (TV) is an ADC targeting tumor expression of tissue factor delivering the cytotoxic warhead MMAE.

InnovaTV 204/ GOG-3023/ENGOT-cx6 is a single arm phase II trial of TV in patients with recurrent/metastatic previously treatment cervix cancer who had measurable disease seeking assessment of objective response by independent radiological review, duration of response and safety.

101 assessable patients were enrolled demonstrating a ORR of 24%, with median duration of response of 8.3 months.

The regimen was well tolerated with the most common treatment-related adverse events being alopecia, epistaxis, nausea, conjunctivitis, fatigue, and dry eye. A rigorous eye care plan can mitigate high grade ocular toxicity.

In previous episodes of Doctor Informed, we've talked about the importance of speaking out, but the culture in your organisation might not always make that easy, especially if you feel something has gone wrong and you might be blamed for it.

Blame culture, no blame culture, just culture - there are many terms which are used to describe the environment in which individuals and teams work, the feel within a team and an organisation. In this episode we'll explore what they mean, why blame can be detrimental to patient safety, and give some tips on how to investigate problems without throwing blame around.

Our guests in this episode;

Joselle Wright - Deputy Director of Midwifery, Gynaecology and Sexual Health at Walsall Healthcare NHS Trust

Susanna Stanford, who became involved in patient safety after experience of a spinal anaesthetic failing during a c-section in 2010. She is an ambassador for the Clinical Human Factors Group.

In this podcast Grainne Donnelly, Associate Prof Izzy Moore and Dr Brooke Patterson speak with Steph about her experience returning to sport post-partum using the 6Rs framework (https://pubmed.ncbi.nlm.nih.gov/34836883/).

Listen to Part 1 first: https://soundcloud.com/bmjpodcasts/bjsm-11022022-ep-497?in=bmjpodcasts/sets/bjsm-1&utm_source=clipboard&utm_medium=text&utm_campaign=social_sharing where Izzy and Grainne discuss the framework and the role of a musculoskeletal clinician.

Return to running BJSM infographic - https://bjsm.bmj.com/content/54/18/1114

Today we focus on NATSAL and NATSAL COVID. These are Britain’s National Surveys of Sexual Attitudes and Lifestyles.

NATSAL has been undertaken every 10 years since 1990 and is a key data source for sexual and reproductive health policy development. However, the COVID-19 pandemic disrupted many aspects of sexual lifestyles, prompting the initiation of the NATSAL-COVID study with the aim of understanding the impact of COVID-19 on sexual behaviour and service use.

Professor Cath Mercer and Professor Nigel Field join us to discuss the results of this study.

All the findings relate to the first four months of lockdown in Britain, which started in March 2020.

Related blog: https://blogs.bmj.com/sti/2022/02/23/natsal-covid-sex-love-and-lockdown/

Relevant Natsal-COVID papers:

- STI paper on sexual behaviour during the pandemic: https://sti.bmj.com/content/early/2021/12/14/sextrans-2021-055210

- Paper in Lancet PH on sexual health services: https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00253-X

- Paper in BMJ Open on sex outside of the household: https://bmjopen.bmj.com/content/12/2/e055284

- Natsal-COVID wave 1 method paper: https://wellcomeopenresearch.org/articles/6-209

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the March 2022 issue of DTB. They talk about paracetamol and its effect on blood pressure and discuss progress on moving to inhalers that have less of an impact on the environment (https://dtb.bmj.com/content/60/3/34). The editors review a study that examined harms from medicines (https://dtb.bmj.com/content/60/3/37) and discuss the use of naldemedine in the management of opioid-induced constipation (https://dtb.bmj.com/content/60/3/39).

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

Type 1 diabetes mellitus is a metabolic disorder characterised by hyperglycaemia due to absolute insulin deficiency. The condition develops due to destruction of pancreatic beta cells, mostly by immune-mediated mechanisms.

In this podcast, Rajesh Garg, Professor of Medicine, University of Miami Miller School of Medicine, gives us an overview of the condition.

For more on type 1 diabetes, visit BMJ Best Practice: bestpractice.bmj.com/topics/en-gb/25

-

The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Drs. Andreas Obermair and Monika Janda to discuss the FeMMe trial.

Highlights:

feMMe was a randomised phase 2 trial testing LNG-IUD alone or in combination with a weight loss intervention or metformin for endometrial hyperplasia with atypia or stage 1 endometrial cancer.

Overall complete pathological response at 6 month was 61%.

Women with endometrial hyperplasia with atypia responded much better than women with endometrial cancer.

Weight loss achieved was moderate and BMI was not associated with response – more work on weight loss interventions needed.

Metformin did not improve response – more biomarker research is needed to understand who will respond to LNG-IUD or not.